HI
NKTR icon

Horizon Investments’s Nektar Therapeutics NKTR Stock Holding History

Horizon Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-643
Closed -$208K – 435
2019
Q4 		$208K Buy
+643
New +$186K 0.01% 505
2019
Q3 		– Sell
-1,043
Closed -$557K – 507
2019
Q2 		$557K Buy
1,043
+368
+55% +$185K 0.02% 234
2019
Q1 		$340K Buy
675
+270
+67% +$160K 0.01% 244
2018
Q4 		$200K Buy
+405
New +$244K 0.01% 196

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Horizon Investments's NKTR Position: Q1 2020 in Review

Horizon Investments sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 643 shares — an estimated $208K sold.

Horizon Investments first reported a position in NKTR in Q4 2018 and held it in 4 quarters. The position peaked at $557K in Q2 2019. 245 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

  • Horizon Investments reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Horizon Investments sold 643 Nektar Therapeutics shares in Q1 2020, an estimated $208K.
  • Horizon Investments first reported a position in Nektar Therapeutics in Q4 2018 and held it in 4 quarters.
  • Horizon Investments's Nektar Therapeutics position peaked at $557K in Q2 2019.
  • 245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Horizon Investments's 13F filing for Q1 2020, filed 15 May 2020.